<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200144</url>
  </required_header>
  <id_info>
    <org_study_id>2837</org_study_id>
    <nct_id>NCT04200144</nct_id>
  </id_info>
  <brief_title>Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial</brief_title>
  <acronym>ESGORT</acronym>
  <official_title>An Open-label, Randomized, Controlled Clinical Trial on the Effects of Endoscopic Sleeve Gastroplasty on Weight, Metabolic Risk Factors, Quality of Life, Satiety, Gastrointestinal Motility and Gut Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, open-label, randomized (2:1), standard medical therapy-controlled&#xD;
      trial.&#xD;
&#xD;
      Subjects in the standard therapy group will be given the opportunity to undergo the active&#xD;
      endoscopic treatment after 6 months of follow up (open label extension) if they will not&#xD;
      achieve an adequate result on body weight. All patients will be followed until the planned&#xD;
      end of the study after 36 months from the ESG procedure.&#xD;
&#xD;
      To study the effects of endoscopic gastroplasty on weight, metabolic risk factors, quality of&#xD;
      life, satiety, gastrointestinal motility and gut microbiota compared to standard medical&#xD;
      treatment control group.&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      - Total body weight loss (%)&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Metabolic risk factors (e.g. lipid profile) and anthropometric measurements (e.g hip and&#xD;
           waist circumference)&#xD;
&#xD;
        -  Body composition&#xD;
&#xD;
        -  Quality of life&#xD;
&#xD;
        -  Gastroesophageal reflux disease&#xD;
&#xD;
        -  Non-Alcoholic Fatty Liver Disease (NAFLD)&#xD;
&#xD;
        -  Non- Alcoholic-Steato-Hepatitis (NASH)&#xD;
&#xD;
        -  Satiety&#xD;
&#xD;
        -  Gut microbiota&#xD;
&#xD;
      Exploratory endpoints:&#xD;
&#xD;
        -  Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin&#xD;
&#xD;
        -  Gastrointestinal motility&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">December 2, 2025</completion_date>
  <primary_completion_date type="Actual">December 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total body weight loss</measure>
    <time_frame>12 months</time_frame>
    <description>Total body weight loss (%) measurement in kg and BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body weight loss</measure>
    <time_frame>36 months</time_frame>
    <description>Total body weight loss (%) measurement in kg and BMI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Alcoholic Fatty Liver Disease evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Non-Alcoholic Fatty Liver Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non- Alcoholic-Steato-Hepatitis evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Non- Alcoholic-Steato-Hepatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota characterization</measure>
    <time_frame>6 months</time_frame>
    <description>Gut microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation for Gastroesophageal reflux disease</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>Gastroesophageal reflux disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin dosages</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>performing of gastric emptying scintigraphy for gastrointestinal motility</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Gastrointestinal motility evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Endoscopic Sleeve Gastroplasty</condition>
  <condition>Gastric Motility</condition>
  <condition>Gastric Hormones</condition>
  <condition>Microbiota</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>active endoscopic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo Endoscopic Sleeve Gastroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard medical therapy control diet group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic sleeve gastroplasty</intervention_name>
    <description>Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)</description>
    <arm_group_label>active endoscopic treatment</arm_group_label>
    <arm_group_label>standard medical therapy control diet group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The participants have to fulfill the following criteria for participating in the study:&#xD;
&#xD;
          -  Age 20 to 65 years&#xD;
&#xD;
          -  BMI between 30 to 45 kg/m2&#xD;
&#xD;
          -  Willingness to participate in the study and ability to comply and understand the study&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Active gastric ulcer during the last 6 months&#xD;
&#xD;
          -  Organic or motility disorder of the stomach and / or esophagus&#xD;
&#xD;
          -  Anticoagulant treatment&#xD;
&#xD;
          -  Previous bariatric surgery or any other type of surgery of the esophagus, stomach and&#xD;
             duodenum&#xD;
&#xD;
          -  Ongoing or active malignancy during the last 5 years&#xD;
&#xD;
          -  Myocardial infarction during the past 6 months or/and heart failure class III or IV&#xD;
             according to the New York Heart association's classification&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Bulimic or binge eating pattern&#xD;
&#xD;
          -  Continuous glucocorticoid or anti-inflammatory treatment&#xD;
&#xD;
          -  Uncontrolled thyroid disease&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Psychiatric or cooperative problems or low compliance that is a contraindication from&#xD;
             participating in the study&#xD;
&#xD;
          -  Hiatal hernia &gt; 5 cm&#xD;
&#xD;
          -  Currently participating in other study&#xD;
&#xD;
          -  Any health issue that might put the patient at risk if the treatment is performed,&#xD;
             judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ivo Boskoski, MD, PhD</last_name>
    <phone>+390630156580</phone>
    <email>ivo.boskoski@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Boskoski, MD, PhD</last_name>
      <phone>00390630156580</phone>
      <email>ivo.boskoski@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

